KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Current Leases (2019 - 2025)

Esperion Therapeutics' Current Leases history spans 7 years, with the latest figure at $2.1 million for Q4 2025.

  • For Q4 2025, Current Leases fell 23.31% year-over-year to $2.1 million; the TTM value through Dec 2025 reached $2.1 million, down 23.31%, while the annual FY2025 figure was $2.1 million, 23.31% down from the prior year.
  • Current Leases reached $2.1 million in Q4 2025 per ESPR's latest filing, down from $2.4 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $2.8 million in Q1 2025 to a low of $305000.0 in Q1 2023.
  • Average Current Leases over 5 years is $1.8 million, with a median of $2.2 million recorded in 2021.
  • Peak YoY movement for Current Leases: plummeted 74.94% in 2023, then skyrocketed 732.46% in 2024.
  • A 5-year view of Current Leases shows it stood at $1.4 million in 2021, then crashed by 72.41% to $384000.0 in 2022, then soared by 304.43% to $1.6 million in 2023, then skyrocketed by 76.5% to $2.7 million in 2024, then fell by 23.31% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Current Leases are $2.1 million (Q4 2025), $2.4 million (Q3 2025), and $2.7 million (Q2 2025).